Cochlear Implantation for Profound Hearing Loss After Multimodal Treatment for Neuroblastoma in Children
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives. Neuroblastoma (NBL) predominantly affects children under 5 years of age. Through multimodal therapy, including chemotherapy, radiotherapy, surgery, and peripheral blood stem cell transplantation, the survival rate in patients with NBL have improved while treatment-related complications have also increased. Treatment-related ototoxicity, mainly from cisplatin, can result in profound hearing loss requiring cochlear implantation (CI). We analyzed the effectiveness and hearing preservation of CI recipients who had treated with multimodal therapy due to NBL. Methods. Patients who received multimodal therapy for NBL and subsequent CIs were enrolled. A detailed review of the perioperative hearing test, speech evaluation, and posttreatment complications was conducted. Speech performance was analyzed using the category of auditory performance (CAP) score and the postoperative hearing preservation of low frequencies was also compared. Patients who were candidates for electro-acoustic stimulation (EAS) used an EAS electrode for low frequency hearing preservation. Results. Three patients were identified and all patients showed improvement of speech performance after CI. The average of CAP score improved from 4.3 preoperatively to 5.8 at 1 year postoperatively. Two patients who were fitted with the Flex electrode showed complete hearing preservation and the preserved hearing was maintained over 1 year. The one remaining patient was given the standard CI-512 electrode and showed partial hearing preservation. Conclusion. Patients with profound hearing loss resulting from NBL multimodal therapy can be good candidates for CI, especially for EAS. A soft surgical technique as well as a specifically designed electrode should be applied to this specific population during the CI operation in order to preserve residual hearing and achieve better outcomes.
Abstract
Objectives. Neuroblastoma (NBL) predominantly affects children under 5 years of age. Through multimodal therapy, including chemotherapy, radiotherapy, surgery, and peripheral blood stem cell transplantation, the survival rate in patients with NBL have improved while treatment-related complications have also increased. Treatment-related ototoxicity, mainly from cisplatin, can result in profound hearing loss requiring cochlear implantation (CI). We analyzed the effectiveness and hearing preservation of CI recipients who had treated with multimodal therapy due to NBL. Methods. Patients who received multimodal therapy for NBL and subsequent CIs were enrolled. A detailed review of the perioperative hearing test, speech evaluation, and posttreatment complications was conducted. Speech performance was analyzed using the category of auditory performance (CAP) score and the postoperative hearing preservation of low frequencies was also compared. Patients who were candidates for electro-acoustic stimulation (EAS) used an EAS electrode for low frequency hearing preservation. Results. Three patients were identified and all patients showed improvement of speech performance after CI. The average of CAP score improved from 4.3 preoperatively to 5.8 at 1 year postoperatively. Two patients who were fitted with the Flex electrode showed complete hearing preservation and the preserved hearing was maintained over 1 year. The one remaining patient was given the standard CI-512 electrode and showed partial hearing preservation. Conclusion. Patients with profound hearing loss resulting from NBL multimodal therapy can be good candidates for CI, especially for EAS. A soft surgical technique as well as a specifically designed electrode should be applied to this specific population during the CI operation in order to preserve residual hearing and achieve better outcomes.
참고문헌 (19)
- Heck JE, "The epidemiology of neuroblastoma: a review", Paediatr Perinat Epidemiol, 23(2), pp.125~143 (2009)
- Cohen LE, "Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems", Bone Marrow Transplant, 49(4), pp.502~508 (2014)
- Landier W, "Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children’s Oncology Group", J Clin Oncol, 32(6), pp.527~534 (2014)
- Brown RF, "Residual hearing preservation after pediatric cochlear implantation", Otol Neurotol, 31(8), pp.1221~1226 (2010)
- Raveh E, "Pattern of hearing loss following cochlear implantation", Eur Arch Otorhinolaryngol, 272(9), pp.2261~2266 (2015)
- Moreno L, "Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience", Pediatr Blood Cancer, 60(7), pp.1135~1140 (2013)
- Gurney JG, "Infant cancer in the U.S.: histology-specific incidence and trends", J Pediatr Hematol Oncol, 19(5), pp.428~432 (1992)
- Spix C, "Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project", Eur J Cancer, 42(13), pp.2081~2091 (2006)
- Brodeur GM, "Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment", J Clin Oncol, 11(8), pp.1466~1477 (1993)
- Brock PR, "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale", J Clin Oncol, 30(19), pp.2408~2417 (2012)
- Gurney JG, "Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children’s Oncology Group", Pediatrics, 120(5), pp.e1229~e1236 (2007)
- Yancey A, "Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients", Pediatr Blood Cancer, 59(1), pp.144~148 (2012)
- Grewal S, "Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group", Pediatrics, 125(4), pp.e938~e950 (2010)
- Roland JT Jr, "Cochlear implantation following treatment for medulloblastoma", Laryngoscope, 120(1), pp.139~143 (2010)
- Knight KR, "Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development", J Clin Oncol, 23(34), pp.8588~8596 (2005)
- Al-Khatib T, "Cisplatinum ototoxicity in children, long-term follow up", Int J Pediatr Otorhinolaryngol, 74(8), pp.913~919 (2010)
- Harris MS, "Fritsch MH. Cisplatin ototoxicity affecting cochlear implant benefit", Otol Neurotol, 32(6), pp.969~972 (2011)
- Chang KW, "Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children", J Clin Oncol, 28(10), pp.1788~1795 (2010)
- Tamir S, "Hearing preservation after cochlear implantation using deeply inserted flex atraumatic electrode arrays", Audiol Neurootol, 17(5), pp.331~337 (2012)